Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine
Pharmacology, Toxicology and Pharmaceutical Science
2
4%
Biochemistry, Genetics and Molecular Biology
2
4%
Agricultural and Biological Sciences
1
2%
Other
3
6%
Unknown
21
41%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 January 2022.
All research outputs
#7,434,196
of 26,558,327 outputs
Outputs from Leukemia
#2,411
of 5,603 outputs
Outputs of similar age
#142,165
of 451,763 outputs
Outputs of similar age from Leukemia
#40
of 93 outputs
Altmetric has tracked 26,558,327 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 5,603 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,763 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 93 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.
